Please assess the completion status of the following clinical trial:

Trial Title: Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with severe aortic stenosis (AVA \< 1.0 cm2)~* Left ventricular hypertrophy~* EF ≥ 45%~* NYHA functional class ≥ 2~* Ambulatory (able to perform a 6 minute walk test)~* Normal sinus rhythm~* 18 years of age and older~* Able and willing to comply with all the requirements for the study~Exclusion Criteria:~* Need for ongoing nitrate medications~* SBP \< 110mmHg or MAP \< 75mmHg~* Moderately severe or severe mitral regurgitation~* Moderately severe or severe aortic regurgitation~* Creatinine clearance \< 30 mL/min~* Increased risk of priapism~* Retinal or optic nerve problems or unexplained visual disturbance~* If a subject requires ongoing use of an alpha antagonist typically used for benign prostatic hyperplasia (BPH) (prazosin, terazosin, doxazosin, or tamsulosin), SBP \< 120 mmHg or MAP \< 80 mmHg is excluded~* Need for ongoing use of a potent CYP3A inhibitor or inducer (ritonavir, ketoconazole, itraconazole, rifampin)~* Cirrhosis~* Pulmonary fibrosis~* Current or recent (≤ 30 days) acute coronary syndrome~* O2 sat \< 90% on room air~* Females that are pregnant or believe they may be pregnant~* Any condition which the PI determines will place the subject at increased risk or is likely to yield unreliable data~* Unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).